Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00043472 | Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk | completed | — | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00068003 | Harvesting Cells for Experimental Cancer Treatments | enrolling by invitation | — | 7,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 |
| NCT00092222 | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | active not recruiting | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00646022 | Natural History of Familial Carcinoid Tumor | recruiting | — | 1,600 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00923507 | Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) | recruiting | — | 1,000 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01087294 | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | completed | Phase 1 | 85 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01109394 | Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies | recruiting | — | 6,035 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01247597 | DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study | recruiting | — | 1,500 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01441089 | Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis | recruiting | — | 1,100 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01445288 | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | completed | — | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01563874 | Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins | completed | — | 130 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01633021 | Developing the Family Map: Looking at Communal Coping | completed | — | 1,061 | National Human Genome Research Institute (NHGRI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01676805 | Tissue Collection for Studies of Lymph Cancer | recruiting | — | 1,295 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT02108028 | Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer | completed | — | 272 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02146170 | Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors | recruiting | — | 2,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02180711 | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 113 | Acerta Pharma BVINDUSTRY | 3 | Sep 28, 2026 | clinicaltrials |
| NCT02473757 | Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02489318 | A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC(TITAN) | active not recruiting | Phase 3 | 1,052 | Aragon Pharmaceuticals, Inc.INDUSTRY | 22 | Sep 28, 2026 | clinicaltrials |
| NCT02595957 | Genomic Services Research Program | recruiting | — | 5,000 | National Human Genome Research Institute (NHGRI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02682667 | Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols | recruiting | — | 500 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02767063 | Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)(ACTIW) | active not recruiting | Phase 1 / Phase 2 | 100 | Versailles HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02791581 | Understanding and Predicting Breast Cancer Events After Treatment(UPBEAT) | active not recruiting | N/A | 403 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03030404 | Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer | completed | — | 733 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03076554 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | active not recruiting | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03223610 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03300830 | Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease | recruiting | — | 280 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03309033 | Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study | active not recruiting | — | 946 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03364621 | Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy(COMPARISON) | active not recruiting | — | 17 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03412877 | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | recruiting | Phase 2 | 285 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03451383 | Older Breast Cancer Patients: Risk for Cognitive Decline(TLC) | recruiting | — | 1,700 | Georgetown UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03462719 | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(GLOW) | active not recruiting | Phase 3 | 211 | Janssen Research & Development, LLCINDUSTRY | 14 | Sep 28, 2026 | clinicaltrials |
| NCT03494569 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome | suspended | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03560752 | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant | active not recruiting | Phase 1 | 34 | City of Hope Medical CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03623464 | RCT of Mobile Apps & FitBit v. Usual Care | suspended | N/A | 107 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03644563 | Men and Women Offering Understanding of Throat HPV(MOUTH) | active not recruiting | — | 1,500 | Johns Hopkins UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03668340 | AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma | active not recruiting | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03734029 | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | completed | Phase 3 | 557 | Daiichi SankyoINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT03762733 | Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies | enrolling by invitation | — | 500 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | terminated | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 28, 2026 | clinicaltrials |
| NCT03865992 | Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease | active not recruiting | N/A | 42 | City of Hope Medical CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03976323 | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | completed | Phase 3 | 1,003 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | active not recruiting | Phase 2 | 50 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04065009 | The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer(IPLA-OVCA) | active not recruiting | Phase 3 | 220 | Karolinska InstitutetOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04071223 | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study | active not recruiting | Phase 2 | 98 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04086485 | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | recruiting | Phase 1 / Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04181827 | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma(CARTITUDE-4) | active not recruiting | Phase 3 | 419 | Janssen Research & Development, LLCINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT04235764 | En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device | recruiting | — | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04235777 | Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies | active not recruiting | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04405401 | Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer(SUPPRESS-NSCLC) | terminated | Phase 2 | 52 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 28, 2026 | clinicaltrials |
Data updated 3 days agoSource updated Sep 28, 2026source: clinicaltrials